•
Dec 31, 2019

ICU Medical Q4 2019 Earnings Report

ICU Medical's fourth quarter results reflected a decrease in revenue compared to the same period last year, but net income improved significantly.

Key Takeaways

ICU Medical reported a revenue of $315.5 million for Q4 2019, a decrease from $340.4 million in Q4 2018. However, the company's net income increased to $20.6 million, or $0.96 per diluted share, compared to a net loss of $7.4 million, or $0.36 loss per diluted share, in the same period last year. Adjusted diluted earnings per share were $1.94, and adjusted EBITDA was $60.7 million.

Q4 2019 revenue was $315.5 million, down from $340.4 million year-over-year.

GAAP net income was $20.6 million, or $0.96 per diluted share, compared to a net loss of $7.4 million, or $0.36 loss per diluted share, in Q4 2018.

Adjusted diluted earnings per share were $1.94, compared to $2.14 in the same period last year.

Adjusted EBITDA was $60.7 million, compared to $69.3 million in the prior year.

Total Revenue
$316M
Previous year: $340M
-7.3%
EPS
$1.94
Previous year: $2.07
-6.3%
Adjusted EBITDA
$60.7M
Previous year: $69.3M
-12.4%
Gross Margin
36%
Previous year: 40%
-10.0%
Gross Profit
$114M
Previous year: $135M
-15.2%
Cash and Equivalents
$269M
Previous year: $345M
-22.1%
Free Cash Flow
$24.8M
Previous year: $32.3M
-23.1%
Total Assets
$1.69B
Previous year: $1.59B
+6.7%

ICU Medical

ICU Medical

ICU Medical Revenue by Segment

Forward Guidance

For the Fiscal Year 2020, the Company expects adjusted EBITDA to be in the range of $240 million to $260 million, and adjusted diluted EPS to be in the range of $6.50 to $7.20.

Revenue & Expenses

Visualization of income flow from segment revenue to net income